This company listing is no longer active
La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
FUREN Group PharmaceuticalLtd Bilan de santé
Santé financière contrôle des critères 2/6
FUREN Group PharmaceuticalLtd has a total shareholder equity of CN¥-2.2B and total debt of CN¥3.2B, which brings its debt-to-equity ratio to -144.8%. Its total assets and total liabilities are CN¥6.2B and CN¥8.4B respectively.
Informations clés
-144.8%
Ratio d'endettement
CN¥3.21b
Dette
| Ratio de couverture des intérêts | n/a |
| Argent liquide | CN¥173.80m |
| Fonds propres | -CN¥2.22b |
| Total du passif | CN¥8.39b |
| Total des actifs | CN¥6.18b |
Mises à jour récentes de la santé financière
Pas de mise à jour
Recent updates
Analyse de la situation financière
Passif à court terme: 600781 has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Passif à long terme: 600781 has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Historique et analyse du ratio d'endettement
Niveau d'endettement: 600781 has negative shareholder equity, which is a more serious situation than a high debt level.
Réduire la dette: 600781's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Bilan
Analyse des pistes de trésorerie
Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.
Piste de trésorerie stable: Whilst unprofitable 600781 has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Prévisions de trésorerie: 600781 is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 6.6% per year.